DRUG DISCOVERY AND DEVELOPMENT IN THE PHARMACEUTICAL-INDUSTRY

被引：0
作者：
SCHACTER, LP
ANDERSON, C
CANETTA, RM
KELLEY, S
NICAISE, C
ONETTO, N
ROZENCWEIG, M
SMALDONE, L
WINOGRAD, B
机构：
来源：
SEMINARS IN ONCOLOGY | 1992年 / 19卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：613 / 621
页数：9
相关论文
共 7 条
  • [1] BURKE G, 1991, P AM SOC CLIN ONCOL, V10, P86
  • [2] JOHNSON JR, 1985, CANCER TREAT REP, V69, P1155
  • [3] THE REGULATION OF INVESTIGATIONAL DRUGS
    KESSLER, DA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (05) : 281 - 288
  • [4] OFF-LABEL DRUG-USE FOR CANCER-THERAPY AND NATIONAL-HEALTH CARE PRIORITIES
    MOERTEL, CG
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 266 (21): : 3031 - 3032
  • [5] COMMENTARY CONCERNING DEMONSTRATION OF SAFETY AND EFFICACY OF INVESTIGATIONAL ANTICANCER AGENTS IN CLINICAL-TRIALS
    OSHAUGHNESSY, JA
    WITTES, RE
    BURKE, G
    FRIEDMAN, MA
    JOHNSON, JR
    NIEDERHUBER, JE
    ROTHENBERG, ML
    WOODCOCK, J
    CHABNER, BA
    TEMPLE, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (12) : 2225 - 2232
  • [6] SCHACTER L, 1990, EARLY PHASE DRUG EVA, P644
  • [7] THE FDAS NEW PROCEDURES FOR THE USE OF INVESTIGATIONAL DRUGS IN TREATMENT
    YOUNG, FE
    NORRIS, JA
    LEVITT, JA
    NIGHTINGALE, SL
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1988, 259 (15): : 2267 - 2270
1